Does Metformin Interfere With the Cardiovascular Benefits of SGLT2 Inhibitors? Questions About Its Role as the Cornerstone of Diabetes Treatment - 23/07/20
Doi : 10.1016/j.amjmed.2020.01.016
Milton Packer, MD a, b, ⁎ 
a Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Tex
b Imperial College, London, UK
⁎Requests for reprints should be addressed to Milton Packer, MD, Baylor Heart and Vascular Institute, 621 N. Hall Street, Dallas, TX 75226.Baylor Heart and Vascular Institute621 N. Hall StreetDallasTX75226
El texto completo de este artículo está disponible en PDF.
| Funding: None. |
|
| Conflicts of Interest: MP served as a consultant for Abbvie, Actavis, Akcea, Amgen, AstraZeneca, Boehringer Ingelheim, Cardiorentis, Daiichi Sankyo, Johnson & Johnson, NovoNordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics and Theravance. |
|
| Authorship: The author is solely responsible for the content of this manuscript. |
© 2020
Elsevier Inc. Reservados todos los derechos.
Vol 133 - N° 7
P. 781-782 - juillet 2020 Regresar al número
Artículo precedente
- Five Questions Every Mentee Should Have an Answer To
- Sanjay Saint, Vineet Chopra
- Multiple Sclerosis and Smoking
- Borros Arneth
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?